A retrospective study of persistence, adherence, and health economic outcomes of fixed-dose combination vs loose-dose combination of oral anti-diabetes drugs

Journal of Medical Economics

Volumn 19, Issue 3, 2016, Pages 203-212

  Lokhandwala, Tasneem ^a   Smith, Nancy ^b   Sternhufvud, Catarina ^c   Sörstadius, Elisabeth ^c   Lee, Won Chan ^a   Mukherjee, Jayanti ^b  

^a XCENDA   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

Adherence; Costs; Diabetes; Fixed dose combination; Persistence

Indexed keywords

ANTIDIABETIC AGENT; DRUG COMBINATION;

ADULT; ARTICLE; COHORT ANALYSIS; COST; HEALTH CARE; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MEDICARE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRESCRIPTION; RETROSPECTIVE STUDY; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; ECONOMICS; FEMALE; INSURANCE; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; UNITED STATES;

DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSURANCE CLAIM REVIEW; MALE; MEDICARE; MEDICATION ADHERENCE; MIDDLE AGED; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84959133478     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2015.1109518     Document Type: Article

References (21)

1. Berlie HD, Garwood CL. Diabetes medications related to an increased risk of falls and fall-related morbidity in the elderly. Ann Pharmacother 2010; 44: 712-7
2. Tamez-Pérez HE, Proskauer-Penã SL, Hernŕndez-Coria MI, et al. AACE Comprehensive Diabetes Management Algorithm. Endocr Pract 2013; 19: 736-37
3. Katsiki N, Athyros VG, Karagiannis A. Single-pill combinations: a therapeutic option or necessity for vascular risk treatment J Drug Assess 2013; 2: 67-71
4. Schernthaner G. Fixed-dose combination therapies in the management of hyperglycaemia in Type 2 diabetes: an opportunity to improve adherence and patient care. Diabet Med 2010; 27: 739-43
5. Williams S, Buysman EK, Hulbert EM, et al. Hemoglobin A1c outcomes and health care resource use in type 2 diabetes mellitus patients treated with combination oral antidiabetic drugs through step therapy and loose-dose and fixed-dose combinations. Manag Care 2012; 21: 40-8
6. Hutchins V, Zhang B, Fleurence RL, et al. A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin 2011; 27: 1157-68
7. Scheen AJ. Saxagliptin plus metformin combination therapy. Exp Rev Endocrinol Metab 2012; 7: 151-64
8. Hiroi S, Sugiura K, Matsuno K, et al. A multicenter, phase III evaluation of the efficacy and safety of a new fixed-dose pioglitazone/glimepiride combination tablet in Japanese patients with type 2 diabetes. Diabetes Technol Ther 2013; 15: 158-65
9. Engel SS, Seck TL, Golm GT, et al. Assessment of AACE/ACE recommendations for initial dual antihyperglycemic therapy using the fixed-dose combination of sitagliptin and metformin versus metformin. Endocr Pract 2013; 19: 751-7
10. Steinberg H, Anderson MS, Musliner T, et al. Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin. Vasc Health Risk Manag 2013; 9: 273-82
11. Melikian C, White TJ, Vanderplas A, et al. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 2002; 24: 460-7
12. Cheong C, Barner JC, Lawson KA, et al. Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients. Clin Ther 2008; 30: 1893-907
13. Bell DS. Combine and conquer: advantages and disadvantages of fixed-dose combination therapy. Diabetes Obes Metab 2013; 15.4: 291-300
14. Benford M, Milligan G, Pike J, et al. Fixed-dose combination antidiabetic therapy: real-world factors associated with prescribing choices and relationship with patient satisfaction and compliance. Adv Ther 2012; 29: 26-40
15. Curkendall SM, Zhang B, Lenhart G, et al. Rate of hypoglycemia in patients with type 2 diabetes receiving metformin plus saxagliptin versus metformin plus sulfonylurea: a retrospective observational cohort study using administrative claims data. Exp Rev Endocrinol Metab 2014; 9: 183-91
16. US Bureau of Labor Statistics. Consumer Price Index. 2014. Available from http://www.bls.gov/cpi/. [Last accessed December 2014].
17. Brook RA, Kleinman NL, Wingenbach D, et al. Medication possession ratio and health benefit cost comparisons in type 2 diabetes patients using fixed-and loose-dose thiazolidinedione combination products. Diabetes 2008; 57 (1 Suppl): A346
18. Colombo GL, Rossi E, De Rosa M, et al. Antidiabetic therapy in real practice: indicators for adherence and treatment cost. Patient Prefer Adherence 2012; 6: 653-61
19. Derosa G, Maffioli P. Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes. Diabetes Metab Syndr Obes 2011; 4: 263-71
20. Garciá-Pérez L-E, Álvarez M, Dilla T, et al. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther 2013; 4: 175-94
21. Doggrell SA, Warot S. The association between the measurement of adherence to anti-diabetes medicine and the HbA1c. Int J Clin Pharm 2014; 36: 488-97